Web Results

www.marketwired.com/press-release/microbix-lawsuit-in-germany-dismissed-without-prejudice-tsx-mbx-2003984.htm

Mar 26, 2015 ... ... Biosystems Inc. (TSX:MBX) ("Microbix" or the "Company"), an innovator of biological products and technologies, announced today that the Court of Dusseldorf, Germany has dismissed its VIRUSMAX® patent infringement lawsuit against Novartis Vaccines and Diagnostics ("Novartis") without prejudice.

www.law360.com/articles/499053/novartis-sued-over-virus-production-patent-for-flu-shots

Jan 6, 2014 ... Microbix Biosystems Inc. alleges that Switzerland-based Novartis Vaccines and Diagnostics Inc. misappropriated Microbix's methodology for upping virus yields during the manufacturing of vaccines and unlawfully relied on it to produce Novartis' Agriflu. “VirusMax is a novel technology that was developed ...

microbix.com/microbix-provides-update-on-u-s-virusmax-litigation

May 15, 2015 ... TORONTO, May 15, 2015 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), an innovator of biological products and technologies, ... and development of biological solutions, including products for human health applications, namely in the vaccine, therapeutic and diagnostic markets, ...

www.mwe.com/en/team/n/nadel-michael-s

Michael S. Nadel is the co-head of the Firm's litigation practice in Washington, DC. He is an accomplished first-chair trial attorney. He has handled numerous jury trials, bench trials and injunction proceedings in federal and state courts around the country. He has won high-profile bet-the-company cases involving claims for ...

www.haugpartners.com/attorney/laura-chubb

Shire Orphan Therapies LLC et al v. InnoPharma Inc., No. 1:16cv00456 (D.Del.) Shire Orphan Therapies LLC et al v. Sandoz Inc., No. 1:15cv01161 (D.Del.) Shire Orphan Therapies LLC et al v. Fresenius Kabi USA, LLC, No. 1:15cv01102 (D. Del.) Supernus Pharmaceuticals, Inc. v. TWI Pharmaceuticals, Inc. et al, No.

www.ncbi.nlm.nih.gov/pmc/articles/PMC4514357

Mar 31, 2015 ... A few manufacturers have taken an intermediate step of enabling technological transfer of assay methodology for their proprietary vaccines to select groups (e.g., Novartis' meningococcal B vaccine) in order to ensure quality assurance by training specific individuals to perform the assay. However, details ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC2621261

Jan 13, 2009 ... GL26 and GL261 were obtained from NCI; LLc1 and B16-F10 cells were obtained from ATCC; and HEK-293 cells were obtained from Microbix. ... MHC I tetramers were obtained from Beckman Coulter Inc. and recombinant human IL-2 (Proleukin) was purchased from Novartis Pharmaceuticals Corporation.

www.accessdata.fda.gov/scripts/cder/ob

One-time report on marketing status for all ANDAs and NDAs required by FDARA section 506I(c) is due February 14, 2018. More information. Effective November 21, 2017, the Orange Book search results and drug listings will display patent submission dates where available. More information ...

www.chinabiotoday.com/sitemap

Renhuang Granted “Key Laboratory” Designation · ChinaBio® Makes "Most Promising Company" Awards · Bayer Seeks Over 20% Annual China Revenue Growth · CRO Sundia MediTech Makes Venture 50 List Again · GSK to Double China R&D Staff · MedMira Granted China Patent for Diagnostic Device · Bridge Labs To ...